we are a nasdaq-listed special purpose acquisition company whose business purpose is to effect a merger or similar business combination with one or more businesses. our acquisition strategy is to identify and complete our initial business combination with a medical technology company in the healthcare industry. our sponsor team consists of chairman/ceo robert palmisano, president vikram malik, cfo oleg grodnensky and chief legal officer david meredith.
Company profile
Ticker
AEON, AEON-WT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Priveterra Acquisition Corp.
SEC CIK
Corporate docs
IRS number
853940478
AEON stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
17 Apr 24
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Regulation FD Disclosure
15 Apr 24
S-1/A
IPO registration (amended)
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
8-K
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
Latest ownership filings
3
Seongsoo Park
18 Apr 24
4/A
Change in insider ownership (amended)
16 Apr 24
4
Change in insider ownership
12 Apr 24
4
Change in insider ownership
26 Mar 24
4
Shelley B Thunen
21 Mar 24
4
ROBERT J PALMISANO
21 Mar 24
4
Marc Forth
21 Mar 24
4
Chad Oh
21 Mar 24
4
JOST FISCHER
21 Mar 24
4
Eric G Carter
21 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
27.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 44 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 593.49 mm |
Total shares | 10.42 mm |
Total puts | 0.00 |
Total calls | 273.85 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Atalaya Capital Management | 3.68 mm | $23.78 mm |
Strathspey Crown | 2.03 mm | $14.26 mm |
Shaolin Capital Management | 794.33 k | $119.00 k |
Cantor Fitzgerald, L. P. | 596.67 k | $89.50 mm |
Davidson Kempner Capital Management | 366.67 k | $55.00 mm |
Aristeia Capital | 358.33 k | $57.30 mm |
Radcliffe Capital Management | 267.63 k | $42.79 mm |
LMR Partners | 250.00 k | $37.50 mm |
Cowen And | 231.96 k | $34.79 mm |
TENOR CAPITAL MANAGEMENT | 166.67 k | $25.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 10.00 mm | - |
11 Apr 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 10.00 mm | - |
24 Mar 24 | Daewoong | Senior Secured Convertible Note Common Stock | Other | Acquire J | Yes | No | 0 | - | 5.00 mm | - |
19 Mar 24 | Alexander Blair Wilson | Stock Option Common Stock | Grant | Acquire A | No | No | 14.4 | 81,300 | 1.17 mm | 81,300 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
19 Apr 24
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
17 Apr 24
Gold Gains 1%; CXApp Shares Spike Higher
1 Apr 24
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
1 Apr 24
Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results
1 Apr 24
Press releases
AEON Biopharma Announces Redemption of Public Warrants
29 Mar 24
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
19 Mar 24